Overexpression of cyclooxygenase-2 (COX-2) in the mouse urinary bladder induces he expression of Immune- And cell proliferation-related genes

Molecular Carcinogenesis

Volumn 48, Issue 1, 2009, Pages 1-13

  Wang, Xingya ^a   Colby, Jennifer K L ^b   Rengel, Robert C ^c   Fischer, Susan M ^b   Clinton, Steven K ^a,c   Klein, Russell D ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Bladder; Cox 2 transgenic mouse; Epiregulin; Gene profile

Indexed keywords

CYCLOOXYGENASE 2; EPIREGULIN; KI 67 ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER CARCINOGENESIS; CANCER MODEL; CELL CYCLE; CELL HYPERPLASIA; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE INDUCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENOME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INCIDENCE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; STRESS; TGFB2 GENE; TGFB3 GENE; TGFBI GENE; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN CULTURE TECHNIQUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

BOVINAE; MUS; MUS MUSCULUS;

EID: 58849089319     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20449     Document Type: Article

References (49)

1. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: Progress and perspective. Cancer Lett 2004;215:1 -20.
2. Klein RD, Van Pelt CS, Sabichi AL, et al. Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression. Cancer Res 2005;65:1808-1813.
3. Hara S, Kondo Y, Matsuzawa I, et al. Expression of cycloxygenase-2 in human bladder and renal cell carcinoma. Adv Exp Med Biol 2002;507:123-126.
4. Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Re 5647-5650.
5. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424-2430.
6. Sweeney CJ, Marshall MS, Barnard DS, et al. Cyclo-oxygen- ase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detect Prev 2002;26:238-244.
7. Gurocak S, Sozen S, Erdem O, et al. Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. Urol Int 2006;76:51 -56.
8. Wadhwa P, Goswami AK, Joshi K, Sharma SK. Cyclo- oxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol 2005;37:47-53.
9. Wulfing C, Eltze E, von Struensee D, Wulfing P, Hertle L, Piechota H. Cyclooxygenase-2 expression in bladder cancer: Correlation with poor outcome after chemotherapy. Eur Urol 2004;45:46-52.
10. Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002;20:651 -656.
11. Wheeler MA, Hausladen DA, Yoon JH, Weiss RM. Prosta- glandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol 2002;168:1568-1573.
12. Khan KN, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
13. Kitayama W, Denda A, Okajima E, Tsujiuchi T, Konishi Y. Increased expression of cyclooxygenase-2 protein in rat urinary bladder tumors induced by N-butyl-N-(4-hydroxybu- tyl) nitrosamine. Carcinogenesis 1999;20:2305-2310.
14. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-5602.
15. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 1998;58:3028-3031.
16. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemo- ther Pharmacol 2000;46:221 -226.
17. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
18. Cohen SM. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 2002;30:663-671.
19. Cohen SM. Urinary bladder carcinogenesis. Toxicol Pathol 1998;26:121 -127.
20. Hosack DA, Dennis G, Jr., Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
21. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Molecular pathways in bladder cancer: Part 2. BJU Int 2005;95:491 -496.
22. Wolff EM, Liang G, Jones PA. Mechanisms of disease: Genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005;2:502-510.
23. Bryan RT, Hussain SA, James ND, Jankowski JA, Wallace DM. Molecular pathways in bladder cancer: Part 1. BJU Int 2005;95:485 - 490.
24. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003;46: S85-S104.
25. Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol 2003;170: 1987-1993.
26. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res 2002;62:4157-4163.
27. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-266.
28. Colquhoun AJ, Mellon JK. Epidermal growth factor receptor and bladder cancer. Postgrad Med J 2002;78:584- 589.
29. Zhu Z, Kleeff J, Friess H, et al. Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000;273:1019- 1024.
30. Shelly M, Pinkas-Kramarski R, Guarino BC, et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998;273: 10496-10505.
31. Nicholson BE, Frierson HF, Conaway MR, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004;64:7813 -7821.
32. Thogersen VB, Jorgensen PE, Sorensen BS, et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest 1999;59: 267-277.
33. Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 2006;15:471 -477.
34. Mohammed SI, Dhawan D, Abraham S, et al. Cyclo oxygenase inhibitors in urinary bladder cancer: In vitro and in vivo effects. Mol Cancer Ther 2006;5:329-336.
35. Harradine KA, Akhurst RJ. Mutations of TGFbeta signaling molecules in human disease. Ann Med 2006;38:403-414.
36. Coombs LM, Pigott DA, Eydmann ME, Proctor AJ, Knowles MA. Reduced expression of TGF beta is associated with advanced disease in transitional cell carcinoma. Br J Cancer 1993;67:578-584.
37. McGarvey TW, Tait E, Tomaszewski JE, Malkowicz SB. Expression of transforming growth factor-beta receptors and related cell-cycle components in transitional-cell carcinoma of the bladder. Mol Urol 1999;3:371 -380.
38. Miyamoto H, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M. Expression of transforming growth factor-beta 1 in human bladder cancer. Cancer 1995;75 2565 - 2570.
39. Kim JC, Steinberg GD. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder. J Urol 2001;165:745- 756.
40. Molinie V, Longchampt E, Ouazana D, Lebret T. Bladder tumors and molecular markers. Current status and perspectives. Ann Pathol 2003;23:306-331.
41. Sharif-Afshar AR, DonohoeJM, Pope JCt, Adams MC, Brock JW III, Bhowmick NA. Stromal hyperplasia in male bladders upon loss of transforming growth factor-beta signaling in fibroblasts. J Urol 2005;174:1704- 1707; discussion 1707.
42. Fang KM, Shu WH, Chang HC, Wang JJ, Mak OT. Study of prostaglandin receptors in mitochondria on apoptosis of human lung carcinoma cell lineA549. Biochem Soc Trans 2004;32:1078-1080.
43. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279:46700-46705.
44. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004;3:1031-1039.
45. Shoji Y, Takahashi M, Kitamura T, et al. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004;53:1151 -1158.
46. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265- 274.
47. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005;65:9304-9311.
48. Tober KL, Wilgus TA, Kusewitt DF, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006;126:205- 211.
49. Miyata Y, Kanda S, Nomata K, Eguchi J, Kanetake H. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 2005;173:56-60.